Sang Myoung Ju

Title: Sang Myoung Ju: Innovator in Human Thrombopoietin Derivatives

Introduction

Sang Myoung Ju is a notable inventor based in Sungnam-si, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of human thrombopoietin derivatives. His work focuses on enhancing platelet production, which is crucial for various medical treatments.

Latest Patents

Sang Myoung Ju holds a patent for "Human thrombopoietin comprising glycosylation sited at residues 157 and 164." This invention relates to novel human thrombopoietin (hTPO) derivatives and the process of their preparation. The innovation involves introducing sugar chains into native hTPO by substituting specific amino acids, resulting in hTPO derivatives with enhanced activities that promote platelet production in vivo. These derivatives may be beneficial for treating thrombocytopenia associated with anticancer therapy or bone marrow transplantation.

Career Highlights

Sang Myoung Ju is associated with Daewoong Pharmaceutical Co., Ltd., where he continues to advance his research and development efforts. His work has the potential to impact the treatment of patients suffering from low platelet counts, thereby improving their quality of life.

Collaborations

Some of his notable coworkers include Joo Young Chung and Sang Kyu Park, who contribute to the collaborative efforts in research and development within the company.

Conclusion

Sang Myoung Ju's innovative work in the field of human thrombopoietin derivatives showcases his commitment to advancing medical science. His contributions are paving the way for new treatments that could significantly benefit patients with thrombocytopenia.